会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • Plasma concentrate apparatus and method
    • 等离子体浓缩装置及方法
    • US20040182788A1
    • 2004-09-23
    • US10394828
    • 2003-03-21
    • Randel DorianRichard Wood Storrs
    • B01D061/00B01D024/00B01D029/00
    • B01J20/28047B01D15/02B01J2220/64B01J2220/68B01L3/5635B01L2300/0681B01L2400/0478G01N1/40G01N1/405Y10T436/25375Y10T436/255
    • A plasma concentrator for producing plasma concentrate from a plasma from which erythrocytes have been substantially removed. The device comprises a concentrating chamber having an inlet port and an concentrate outlet, the concentrating chamber containing hydrogel beads and at least one inert agitator; and a concentrate chamber having an inlet communicating with the concentrator outlet through a filter, and having an plasma concentrate outlet port. A process for producing plasma concentrate from plasma from which erythrocytes have been substantially removed, comprising the steps of a) moving the plasma into a concentrating chamber containing hydrogel beads and an agitator to form a hydrogel bead-plasma mixture; b) causing the agitator to stir the hydrogel bead-plasma mixture, facilitating absorption of water by the beads from the plasma, until a hydrogel bead-plasma concentrate is formed; and c) separating the plasma concentrate from the hydrogel beads by passing the plasma concentrate through a filter. The concentrator can be one or more syringe devices coupled for multiple concentrations.
    • 用于从已经基本上除去红细胞的血浆中产生血浆浓缩物的血浆浓缩器。 该装置包括具有入口和浓缩物出口的浓缩室,该浓缩室含有水凝胶珠和至少一种惰性搅拌器; 以及浓缩物室,其具有通过过滤器与浓缩器出口连通并具有等离子体浓缩物出口的入口。 一种用于从已经基本上除去红细胞的血浆中产生血浆浓缩物的方法,包括以下步骤:a)将血浆移动到含有水凝胶珠和搅拌器的浓缩室中以形成水凝胶珠 - 等离子体混合物; b)使搅拌器搅拌水凝胶珠 - 等离子体混合物,促进珠粒从等离子体吸收水分,直到形成水凝胶珠 - 浆料浓缩物; 和c)通过使血浆浓缩物通过过滤器将血浆浓缩物与水凝胶珠分离。 浓缩器可以是连接多个浓度的一个或多个注射器装置。
    • 7. 发明申请
    • Concentrator and filter based blood treatment system
    • 集中器和过滤器血液处理系统
    • US20040182784A1
    • 2004-09-23
    • US10391455
    • 2003-03-17
    • Kimberly A. WalkerAlan A. DavidnerScott R. Mallett
    • B01D061/00
    • A61M1/3681A61L2/0011A61L2/0017A61M1/3431A61M1/3441A61M1/3468A61M1/3472A61M1/3683A61M2205/053A61M2205/75
    • A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient's cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.
    • 提供了一种预防和治疗患者血液中败血症的方法和装置。 体外系统包括用于灭活至少99%的血源性微生物的抗微生物装置,血液浓缩器/过滤单元以从患者血液中除去大约50-75%的靶分子,以及过滤器单元以从筛选的患者血液中除去靶分子 血浆滤液。 靶分子由微生物以及患者的细胞产生。 这些分子包括来自革兰氏阴性细菌的内毒素,来自革兰阴性和革兰氏阳性细菌的外毒素,以及来自金黄色葡萄球菌的RAP蛋白质介质,以及细胞介质如肿瘤坏死因子-α和白介素1-β,白细胞介素6,补体蛋白 C3a和C5a以及缓激肽。